RisX
OncoSim
Evidence-conscious oncology payer research workspace
SEER tumor site
State
SEER summary stage
All
Localized
Regional
Distant
Unknown
Cost profile
Flagship drug annualization
Source component scenario
CMS 2026Q4 source scenario
Payer mix / book of business
All-Payer Blended
Medicare Advantage
Commercial
Tissue sufficiency / NGS yield:
80%
Regimen uptake:
100%
Scenario assumptions (editable; these are model inputs, not source data)
Clinical
Epidemiology, tissue cascade, FDA outcomes
--
Economic & HEOR
Budget impact, scenario model, ROI
--
Patient Focus
Trial matching and treatment guide
--
Cross-Analysis Studio
Tumors, 5 states, sensitivity
--
Plan Benefit Design & Clinical Pathways
PA/UM checklist, pathway optimizer, pre-1L incentive
31-Tumor Frontier
5-State Payer Benchmark
Sensitivity Matrix
Export Table to CSV
Generate Executive Brief (Print / PDF)